This finding is consistent with the study by Evcil FY et al., which reported that underweight patients with advanced EGFR-mutated NSCLC had 2.08-fold (95% CI: 1.05–4.14) higher risk of death compared to those with normal weight [25]. Here, EGFR is linked to non-small cell lung carcinoma.